Tamtam Try Tamtam free
Sotera Health Company logo

Sotera Health Company account plan

Global health safeguarding expertise

At a glance

Sotera Health provides sterilization, Co-60 supply and lab testing to healthcare makers; FY2025 revenue was $1,163.6 million across 62 facilities.

Sotera Health (Nasdaq: SHC, Broadview Heights, Ohio) provides end-to-end sterilization, lab testing and advisory services for the healthcare industry, helping make medical, pharmaceutical and food products safe. Its customers in over 50 countries included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies in 2025. FY2025 net revenues were $1,163.6 million (+5.7%), net income $77.9 million and Adjusted EBITDA $593.8 million. It runs 62 facilities with over 3,000 employees, and its former private equity sponsors sold their last shares in May 2026.

Business units

Strategic priorities

Accelerating growth through One Sotera
CEO Alton Shader's goal is to accelerate growth by selling the full offering across units; about 70% of Sterigenics and Nelson Labs revenue comes from shared customers.
Sterilization capacity expansion
The North Carolina X-ray facility started revenue in Q3 2026, and a second greenfield project is due around end of 2027 or early 2028; U.S. EO capacity, especially large chambers, is tight.
Securing Co-60 supply
Nordion develops new Co-60 sources with Westinghouse, where PSEG is to be the first U.S. utility producing Co-60, and at the Darlington reactors in Ontario.
Free cash flow and deleveraging
Net leverage reached 2.9x against a 2-3x target after a Moody's upgrade; capex should step down meaningfully in 2027, toward the Investor Day free cash flow objective of $500 to $600 million.
Disciplined M&A
Management names strategic M&A focused on sterilization services, with share repurchase and debt paydown also evaluated with the board.

Latest results

In Q3 2026 (quarter ended September 30, 2026), net revenues were $324.9 million (+4.4%), net income $58.4 million and Adjusted EBITDA $170.7 million (+3.9%), with the adjusted EBITDA margin up nearly 100 basis points sequentially to 52.5%. Sterigenics grew 8.5% and Nelson Labs 8.8%, while Nordion fell 12.4% on Co-60 harvest timing. For the nine months, revenues were $926.3 million (+7.7%) and Adjusted EBITDA $471.1 million (+7.9%). The 2026 outlook was reaffirmed at revenue of $1.233-1.250 billion and adjusted EBITDA of $632-641 million, with Sterigenics Q4 revenue expected flat sequentially because of softer European med device demand.

Investments and deals

Capex program
Capex was $145.5 million in the first nine months of 2026 (vs $87.3 million), with full-year 2026 capex guided at $200-225 million.
EO facility environmental enhancements
$24.4 million of 2025 capex and about $51 million expected in 2026 to meet U.S. EPA NESHAP and other rules; the work finishes in Q1 2027.
X-ray and greenfield sites
A new X-ray facility in North Carolina began revenue in Q3 2026, and a second greenfield project is back on, due towards the end of 2027 or early 2028.
Nelson Labs pharma testing expansion
Lab expansion for pharma testing, with new commercial leadership put in place to drive core lab growth.
Debt refinancing
The term loan was repriced in May 2026 to SOFR + 2.25% on $1,415.9 million, maturing May 2031; the weighted average rate fell to 6.44% in Q3 2026.

Challenges and risks

Ethylene oxide litigation
About 450 personal injury claims are pending in Georgia and about 120 claims in California, with first trials in January and April 2027; EO litigation and professional fees were $46.2 million in 2025.
Co-60 supply concentration
About 20% of long-term Co-60 supply is expected from Russian reactors, up to about 50% in a given year, exposed to sanctions and shipping licence renewals.
EO regulation
EPA NESHAP rules, the FIFRA Interim Decision and California requirements impose new emission controls and worker exposure limits; in the U.S. Sterigenics buys all its EO from one supplier.
Softer med device demand
Med device demand softened from mid-to-late Q3 2026, mostly among European customers, and continued into early Q4.

What leadership says

“my primary goal is to be able to accelerate growth within this business. We got to become more essential to our customers. We've got to become easier to work with.”

Alton Shader, Chief Executive Officer · Q2 2026 earnings call, August 6, 2026

“We've got approximately 70% of our Sterigenics and Nelson Labs revenue comes from shared customers and we obviously need to focus on penetrating these accounts with our full offering.”

Alton Shader, Chief Executive Officer · Q3 2026 earnings call, November 3, 2026

“this is an incredibly resilient business.”

Alton Shader, Chief Executive Officer · Q3 2026 earnings call, November 3, 2026

“We definitely see a meaningful step down in CapEx next year”

Jon Lyons, Chief Financial Officer · Q3 2026 earnings call, November 3, 2026

Where a supplier can help

Emission control and EHS solutions
Tied to EO regulation and the facility enhancements finishing in Q1 2027: emission control, monitoring and worker-safety suppliers fit the about $51 million of 2026 environmental capex.
Construction and equipment for new capacity
Tied to sterilization capacity expansion: builders and equipment vendors can support the second greenfield project and X-ray capacity.
Cross-selling and CRM tooling
Tied to the One Sotera priority: account management and CRM tools help penetrate shared Sterigenics and Nelson Labs customers with the full offering.
Supply chain risk management
Tied to Co-60 supply concentration and the single EO supplier: sourcing, logistics and risk-monitoring partners address supply exposure.
Lab capacity for pharma testing
Tied to the Nelson Labs pharma testing expansion: lab equipment, LIMS and staffing partners support growth in core lab testing.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Sotera Health Company?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Sotera Health Company

What does Sotera Health do?

Sotera Health sterilizes medical, pharmaceutical and food products through Sterigenics, supplies Co-60 through Nordion and runs lab testing and advisory services through Nelson Labs.

What is Sotera Health's revenue?

FY2025 net revenues were $1,163.6 million, up 5.7%. 2026 revenue is guided at $1.233-1.250 billion.

How many employees does Sotera Health have?

Sotera Health had over 3,000 employees across 62 facilities at December 31, 2025.

Who leads Sotera Health?

Alton Shader became CEO on May 26, 2026; Michael Petras is Executive Chairman after ten years as CEO, and Jon Lyons is CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)